Related Experiment Video
Updated: Jun 7, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Iron supplementation to treat anemia in patients with chronic kidney disease
Anatole Besarab1, Daniel W Coyne
1Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI 48301, USA.
Insights
Iron deficiency is common in chronic kidney disease (CKD). Intravenous iron is more effective than oral iron for managing anemia in hemodialysis patients, reducing the need for erythropoiesis-stimulating agents (ESAs).
Area of Science:
- Nephrology
- Hematology
- Nutritional Science
Background:
- Iron deficiency is a significant issue for patients with chronic kidney disease (CKD).
- Anemia in CKD patients is often linked to iron deficiency, impacting treatment efficacy.
- Erythropoiesis-stimulating agents (ESAs) are commonly used but their effectiveness can be limited by iron status.
Purpose of the Study:
- To review the efficacy and safety of iron supplementation in treating anemia in CKD patients.
- To compare oral versus intravenous iron administration in CKD populations.
- To discuss the role of iron in patients undergoing dialysis versus those not requiring dialysis.
Main Methods:
- Review of existing literature on iron supplementation in chronic kidney disease.
- Analysis of studies comparing oral and intravenous iron formulations.
- Examination of iron metabolism and hepcidin levels in CKD patients.
Main Results:
- Intravenous iron is superior to oral iron in hemodialysis patients, improving hemoglobin levels and reducing ESA requirements.
- Elevated hepcidin levels in CKD patients impair oral iron absorption and iron recycling.
- Specific ferritin and transferrin saturation levels indicate iron deficiency, but high values lack diagnostic utility in dialysis patients.
Conclusions:
- Iron supplementation is crucial for managing anemia in CKD patients.
- Intravenous iron administration is preferred for hemodialysis patients due to absorption issues with oral iron.
- Advances in iron delivery methods should improve iron provision for CKD patients.
Abstract:
Iron deficiency is prevalent in patients with chronic kidney disease (CKD), and use of oral and intravenous iron in patients with CKD who do not require dialysis might obviate or delay the need for treatment with eythropoiesis-stimulating agents (ESAs). Patients on hemodialysis have lower intestinal iron absorption, greater iron losses, and require greater iron turnover to maintain the ESA-driven red cell mass than do healthy individuals. In these patients, intravenous iron reduces ESA dose requirements and increases the likelihood of maintaining levels of hemoglobin within the desired range. Oral iron is inferior to intravenous iron in patients on hemodialysis, in part because elevated serum levels of hepcidin prevent intestinal absorption of iron. Increased levels of hepcidin also impair the normal recycling of iron through the reticuloendothelial system. Levels of serum ferritin and transferrin saturation below 450 pmol/l and 20%, respectively are indicative of iron deficiency, but values above the normal range lack diagnostic value in patients with CKD on dialysis. The availability of various iron preparations and new developments in delivering iron should enable adequate provision of iron to patients with CKD. This Review examines the efficacy, safety and use of iron supplementation therapy for the treatment of anemia in patients with CKD.
More Related Videos
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease I: Introduction
Acute Kidney Injury V: Interprofessional Care
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease IV: Nursing Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention

